ADVERTISEMENT
Natco Pharma Q2: Stock Correction Warrants Dolat Capital's 'Add' Upgrade — Check Revised Target Price
With the recent stock correction, Dolat Capital believes there is an upside and upgrade rating to ‘Accumulate’ from Sell.
15 Nov 2025, 11:32 AM IST 
Save
Llaunch of Semaglutide can be a good uptick in Natco Pharma's domestic sales post-patent expiry in FY26, with potential to achieve sales of Rs 1 billion. (Photo: Envato)
Natco Pharma’s Q2 FY26 sales were below estimates due to lower-than expected other operating income and domestic formulation business, while crop health was better than expected. PAT came above estimates.
